FDA draft guidance aims to streamline gene therapy development
New document may matter for rare diseases such as AADC deficiency
Written by |
The U.S. Food and Drug Administration (FDA) has issued draft guidance meant to help developers of human gene therapies involving genome editing bring treatments to patients more efficiently, including those with rare and life-threatening diseases. Some recommendations also may apply to other cell and gene therapy products, including adeno-associated viral vectors, or AAV vectors.
While the guidance is not specific to aromatic L-amino acid decarboxylase (AADC) deficiency, it may be relevant to the broader rare disease gene therapy field, where small patient populations can make traditional drug development especially challenging.
Guidance may have broader gene therapy relevance
AADC deficiency currently has an FDA-approved gene therapy, Kebilidi (eladocagene exuparvovec-tneq), making it part of a growing treatment area that may be informed by evolving FDA guidance on gene therapy development.
The draft guidance describes how therapy developers may use existing scientific and regulatory knowledge — including manufacturing, nonclinical study results, and clinical information — to reduce redundant testing and streamline submissions for gene therapy products.
“Today’s action reflects the FDA’s commitment to get safe and effective cell and gene therapies to patients faster, particularly those living with rare and life-threatening diseases who have few or no other treatment options,” Karim Mikhail, acting director of the Center for Biologics Evaluation and Research (CBER), said in an FDA press release.
“By providing information on how companies may build on what is already known we are accelerating innovation without compromising the rigorous scientific standards that patients and the public depend on. Ultimately, this is about making sure that the promise of gene therapy reaches the patients who need it most, as quickly and safely as possible,” Mikhail added.
AADC deficiency is a rare genetic disease caused by mutations in the DDC gene. This gene provides instructions for making the AADC enzyme, which helps nerve cells produce dopamine and serotonin, two key brain signaling molecules.
Kebilidi is approved for AADC deficiency
In November 2024, the FDA approved Kebilidi as the first gene therapy for AADC deficiency in adults and children. The treatment is an adeno-associated virus, or AAV, vector-based therapy designed to deliver a working copy of the DDC gene so cells can produce the AADC enzyme.
The new guidance is intended to help developers of human gene therapies involving genome editing build on prior knowledge when scientifically justified. According to the FDA, companies would still need to explain why existing information applies to their specific product and development program.
The draft guidance is also part of a broader FDA effort on gene therapy development, including actions related to genome-editing safety and development of therapies for serious or rare diseases.
“By outlining how sponsors can intelligently build upon existing nonclinical, clinical, and manufacturing knowledge, we can meaningfully streamline development programs and lower the cost barriers that have historically slowed access to these potentially life-changing treatments,” said Vijay Kumar, MD, acting director of the Office of Therapeutic Products in CBER.
“Leveraging prior knowledge does not mean lowering the bar; it means raising our collective efficiency while maintaining the highest standards of safety and efficacy. For patients living with serious or rare diseases, time matters. We encourage developers to engage with this guidance because their perspectives are essential to shaping a regulatory framework that works for everyone, and most importantly, for the patients who are counting on us,” Kumar added.
Rare disease programs often face data limits
For conditions such as AADC deficiency, where the number of patients is very small, development programs often rely on limited datasets and careful comparisons with what is already known about the disease and related therapies. The FDA’s draft guidance could help clarify how developers may use such information in future gene therapy programs, while still meeting safety and effectiveness standards.
The FDA also encouraged developers to meet with the agency early in development, including before submitting an investigational new drug application, to discuss how they plan to use prior knowledge.
“We look forward to working closely with sponsors to help them understand how to effectively implement this guidance and leverage prior knowledge in their development programs,” said Denise Gavin, PhD, director of the Office of Therapeutic Products’ Office of Gene Therapy — CMC.
The draft guidance is open for public comment. Comments must be submitted within 90 days of publication in the Federal Register, after which the FDA will review feedback before finalizing the guidance.
Leave a comment
Fill in the required fields to post. Your email address will not be published.